demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
ruxolitinib Cao DEVENT

1 studies excluded by filtering options 1

6490 Kaplanski, 2020 0300selection pending